ATE183651T1 - Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen - Google Patents

Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen

Info

Publication number
ATE183651T1
ATE183651T1 AT93913735T AT93913735T ATE183651T1 AT E183651 T1 ATE183651 T1 AT E183651T1 AT 93913735 T AT93913735 T AT 93913735T AT 93913735 T AT93913735 T AT 93913735T AT E183651 T1 ATE183651 T1 AT E183651T1
Authority
AT
Austria
Prior art keywords
pct
gastrointestinal disorders
igf
growth factor
sec
Prior art date
Application number
AT93913735T
Other languages
English (en)
Inventor
Peter David Gluckman
David James Mellor
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE183651T1 publication Critical patent/ATE183651T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT93913735T 1992-06-08 1993-06-07 Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen ATE183651T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ243071A NZ243071A (en) 1992-06-08 1992-06-08 Igf-2 (or analogue) compositions for pharmaceutical uses

Publications (1)

Publication Number Publication Date
ATE183651T1 true ATE183651T1 (de) 1999-09-15

Family

ID=19924004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913735T ATE183651T1 (de) 1992-06-08 1993-06-07 Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen

Country Status (9)

Country Link
US (1) US5482926A (de)
EP (1) EP0602211B1 (de)
JP (1) JPH06510066A (de)
AT (1) ATE183651T1 (de)
AU (1) AU670296B2 (de)
CA (1) CA2114420A1 (de)
DE (1) DE69326122D1 (de)
NZ (2) NZ260309A (de)
WO (1) WO1993025227A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
CA2114419A1 (en) * 1992-06-08 1993-12-23 Peter D. Gluckman Use of growth factor igf-i and/or igf-ii
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU689719B2 (en) * 1995-05-02 1998-04-02 Novozymes Biopharma Dk A/S Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
US5814308A (en) * 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
DE69719190D1 (de) * 1996-07-02 2003-03-27 Pharmaproducts Uk Ltd Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP1212066A4 (de) * 1999-08-09 2004-03-03 Univ Maryland Pro-intestinale reifung und entzündungshemmende wirkung des lactobacillus und der von lactobacillus sekretierten proteinen, kohlenhydraten und lipiden
KR102313381B1 (ko) * 2013-12-19 2021-10-14 퓨어테인 바이오사이언스, 엘엘씨. 동물을 치료하기 위한 방법
WO2016184427A1 (zh) * 2015-05-21 2016-11-24 中国科学院上海生命科学研究院 低氧处理的间充质干细胞及其应用
CN108114271B (zh) * 2016-11-29 2021-07-02 中国科学院上海营养与健康研究所 含胰岛素样生长因子-2的药物组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005822A1 (en) * 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
EP0429586B1 (de) * 1989-06-09 1995-08-02 Gropep Pty. Ltd. Wachstumshormonfusionsproteine
ATE165008T1 (de) * 1990-02-13 1998-05-15 Gropep Pty Ltd Methode zur behandlung intestinaler krankheiten
NZ234439A (en) * 1990-07-10 1997-08-22 Pharmacia & Upjohn Ab Use of igf-1 to reduce fetal growth retardation in non human mammals
IE912345A1 (en) * 1990-08-03 1992-02-12 Pharmacia Ab Treatment of human lactation failure
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning

Also Published As

Publication number Publication date
AU4366293A (en) 1994-01-04
EP0602211A1 (de) 1994-06-22
NZ260309A (en) 1997-07-27
AU670296B2 (en) 1996-07-11
DE69326122D1 (de) 1999-09-30
CA2114420A1 (en) 1993-12-23
NZ243071A (en) 1994-09-27
JPH06510066A (ja) 1994-11-10
US5482926A (en) 1996-01-09
WO1993025227A1 (en) 1993-12-23
EP0602211B1 (de) 1999-08-25

Similar Documents

Publication Publication Date Title
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE151293T1 (de) Igf-i zur verbesserung der neuronale lage
ATE203165T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndromes
EP1201241B8 (de) Zusammensetzungen enthaltend Capsaicin oder Capsaicin Analoge und ein Anästhetikum
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE207351T1 (de) Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
DE60305055D1 (de) Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten
AU690853B2 (en) Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE246511T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
Gluckman et al. Growth factor IGF-IL
NO940383L (no) Anvendelse av vekstfaktor IGF-I og/eller IGF-II

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties